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metabolism is reduced in patients with preexisting liver disease
and statins are known to increase ALT [3,4], with a slight dose
dependency of ALT increase for higher statin doses ([4], Table 3).
At no time did Björnsson et al. [2] claim a dose dependent sta-
tin hepatotoxicity, but described a rare, severe idiosyncratic
statin hepatotoxicity; reexposure with similar symptoms nearly
proves a causal relationship. Bader should have withdrawn his
previous statement concerning the myth of statin hepatotoxicity
[5], because this proposal was incorrect and misleading; consid-
ering the very low incidence in clinical studies, spontaneous
reports, and case reports, the decision still will result in prescrib-
ing statins rather than withholding them.
Most systems to detect rare ADRs rely upon active reporting
systems where cases are only included if physicians suspect a
causal relationship. These systems are heavily biased toward
assuming causality even if this does not exist; the dilemma of
prejudice and selective data reporting, as is prevalent for other
cases of potential hepatotoxicity by drugs and herbs, was ele-
gantly solved by Björnsson et al. using the diagnostic algorithm
of CIOMS, also called RUCAM [2]. Despite its known shortcom-
ings, this causality assessment method has been used extensively
to evaluate hepatotoxicity by drugs [6]. In relation to the study on
statin hepatotoxicity by Björnsson et al. [2], the applied method
of CIOMS/RUCAM was considered the best method available for
this inquiry [1].
Björnsson et al. [2] identiﬁed cases of idiosyncratic hepatotox-
icity due to statins and discussed their results regarding previous
reports on other cases of statin hepatotoxicity. This conﬁrms that
package inserts of warnings about the rare hepatotoxicity
problem should remain, as opposed to the viewpoint of Bader
who prefers its deletion [5]. The cautionary statement is valuable
information for physicians and patients and a preventive
measure for legal consequences that otherwise may reach statin
manufacturers in cases of statin hepatotoxicity.
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Reply to: ‘‘Statin hepatotoxicity and the dilemma of causality
in rare hepatic adverse drug reactions’’
To the Editor:
ALT monitoring for statins no longer recommended
It is gratifying that since the publication of my editorial review on
statins and the liver (February 2012 issue of the Journal), the USA
Food and Drug Administration (FDA) announced on 28 February
2012, a marked relaxation of package insert language on all stat-
ins [1]. Since pharmaceutical safety boards of many countries clo-
sely follow the insert language of the FDA, these revisions will be
of interest to a worldwide audience.
What was previously a hodge-podge of comments about the
liver that differed for each statin, the discussion has been greatly
redacted and made uniform. Brieﬂy, the statin labels no longer
recommend ALT monitoring after starting a statin. Should acute
liver disease develop, the statin should be withheld until the
cause is ascertained. This would imply that the patient should
be told before treatment about possible signs of drug-induced
liver injury and urged to inform the physician if these symptoms
occur. The label reminds the reader that an ALT elevation can also
occur from muscle injury.
These changes represent a seismic shift in policy. The FDA
clearly agrees that an elevated ALT after initiating a statin is
not a sign of hepatotoxicity. Instead, the shift in monitoring for
symptoms follows the same successful approach as for isoniazid
monitoring. I have advocated these changes for some time [2–4].
Still, the labels advise that liver tests be checked prior to ini-
tiating a statin, and that statins should not be given to patients
with ‘‘active liver disease.’’ The phrase ‘‘active liver disease’’ is
not deﬁned on the label nor anywhere else I am aware of.
The correspondents and I both agree that statins can be given
to patients with chronic liver disease. There is reasonable dis-
agreement over use in decompensated liver patients simply due
to a lack of data. However, data are starting to appear. In Spain,
Abraldes et al. gave 40 mg of simvastatin or placebo to 60 cirrho-
tics with portal hypertension (proved by WHVP) in a randomized
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controlled fashion over 30 days. The intervention group experi-
enced a signiﬁcant decrease in portal hypertension that was addi-
tive to the effects of propranolol. Moreover, liver tests increased
more often with placebo than simvastatin [5].
The correspondents generalize, without support, that non-
USA physicians have no trouble giving statins to patients with
liver disease. In the editorial, I cite an international HCV treat-
ment study where the majority of authors are not from the USA
[6]. Only 3% of the 403 patients were on statins; whereas, given
the customary age range for participants in HCV studies, one
would expect 30% or more of these latter study patients to need
a statin. These data would seem to indicate a bias by hepatolo-
gists worldwide not to give statins to patients who have at least
hepatitis C disease.
The problem the correspondents fail to apprehend with
RUCAM methodology is its extremely low positive predictive
value (PPV). With RUCAM, the probability of a statin being cor-
rectly identiﬁed as the ‘‘true’’ cause of idiopathic test abnor-
malities is less than 1% [4]. That is, if the RUCAM determines
the statin is the culprit, 99 out of a 100 times it is wrong.
Not the type of certainty one would want in a court of law,
for example. While this level of uncertainty may be sufﬁcient
to withdraw a drug from a patient, it is not compelling enough
to conclude scientiﬁcally that statins cause idiosyncratic
reactions. Thus, there remains legitimate doubt as to whether
statins are responsible for rare instances of idiosyncrasy. All
of the cases presented by Bjornsson et al. could easily be
counted as background noise [7]. Nevertheless, until we
become more scientiﬁc and settle the issue with proteomics
and microarray testing, we are stuck with clinical opinion;
the variations of RUCAM represent only attempts to score clin-
ical judgment with numbers.
The terminology for the subject is critical otherwise the reader
will confuse what the message of statin mythology has been all
about. The letter writers use the term ‘‘hepatotoxicity’’ both as
a general term, and for predictable dose-dependent reactions. I
believe universal practice is to now use ‘‘DILI’’ or ‘‘drug-induced
liver injury’’ as a general term, and restrict hepatotoxicity to
the predictable, dose-dependent setting [8].
The remaining concerns of the correspondents have become
moot since the revisions of 28 February 2012 by the FDA.
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Which is the real efﬁcacy of pegylated interferon alpha 2a or 2b
plus ribavirin in HCV infected patients with advanced ﬁbrosis?
To the Editor:
We have read with great interest the article of Prati et al. [1]. The
authors concluded that patients infected with HCV genotypes
1–4 that received PegIFNa-2A plus ribavirin with advanced ﬁbro-
sis (staging P3 according to Ishak classiﬁcation) had an end
treatment response (ETR) and sustained virological response
(SVR) rates that were not inﬂuenced by ﬁbrosis stage. In contrast,
PegIFNa-2B plus ribavirin was less effective than PegIFNa-2A and
led to a lower rate of both ETR and SVR in patients with staging
P3. We are concerned about part of the content of the paper.
The article analyzed a heterogeneous population of patients
infected with HCV that included ‘‘difﬁcult to treat patients’’
infected with genotypes 1–4 and ‘‘easy to treat patients’’ infected
with genotypes 2 and 3. Those infected with HCV genotypes 1-4
were analyzed together and stratiﬁed according to the Ishak clas-
siﬁcation staging score. However, several questions remain unan-
swered: What was the distribution of patients with genotype 4 in
the different staging groups? What was the percentage of Egyp-
tian patients in the genotype 4 group included in the study? In
Northern Italy, HCV genotype 4 was reported in about 2% of all
patients infected with HCV [2]. In addition, different studies have
reported that patients infected with genotype 4 presented a bet-
ter SVR compared to those infected with genotype 1, particularly
in patients that achieved a rapid virological response (RVR) [3,4].
Furthermore, Egyptian patients infected with genotype 4 with
advanced ﬁbrosis had a better SVR compared to European and
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